Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Latest News

The findings have potential implications for treatment selection in CLL/SLL, particularly in patients at elevated risk for infectious complications. | Image credit: Eleni - stock.adobe.com
Higher Infection Risk With Venetoclax-Obinutuzumab vs Zanubrutinib in CLL/SLL

July 7th 2025

Patients with chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL) treated with venetoclax plus obinutuzumab experienced significantly higher rates of serious infections compared with those receiving zanubrutinib, according to real-world data.

Clinical trial graphic | Image credit: photon_photo - stock.adobe.com
Comparative Analysis Suggests Zanubrutinib as Most Effective cBTKi in R/R CLL

July 5th 2025

CLL cells | Image Credit: © sovova - stock.adobe.com
MRD-Guided Ibrutinib Plus Venetoclax Effective in R/R CLL

June 30th 2025

After adjustment for imbalances, patients in the liso-cel group had an overall response rate of 52.5%, compared with 19.2% in the standard-of-care group. | Image credit: fotogurmespb- stock.adobe.com
Liso-Cel Improves Outcomes in R/R CLL/SLL Following 2 or More Lines of Therapy

June 26th 2025

Venetoclax showed “remarkable efficacy” in older patients, with an response rate of 91% in the octogenarian group—similar to what has been reported in younger cohorts. | Image credit: sovova - stock.adobe.com
Venetoclax Effective in Older Patients With CLL

June 20th 2025

More News

Precision medicine | Image Credit: leowolfert-stock.adobe.com
August 8th 2024

Opportunities Remain for Expanding Precision Medicine in CLL

AJMC Contributor
As the treatment landscape for chronic lymphocytic leukemia (CLL) has moved into an era where targeted treatments are a mainstay of treatment, new opportunities to tailor therapy have emerged.
biomarker word cloud | Image Credit: laufer-stock.adobe.com
August 4th 2024

Biomarker Incorporated Into Novel CLL Outcome Prediction Model

Gayle Turim Dickstein
Researchers believe that in their revised 4-factor model to predict patient outcomes in chronic lymphocytic leukemia (CLL), CD49d tops lactate dehydrogenase.
concept of a genetic mutation | Image Credit: © lucadp - stock.adobe.com
August 1st 2024

Co-Occurrence of del(6q), RPS15 May Drive Poor Prognosis in CLL

AJMC Contributor
The findings support previous research suggesting that worse prognosis in patients with del(6q) is not solely a result of genomic instability or presence of multiple genetic alterations.
Clinical link research | Image Credit: sdecoret - stock.adobe.com
July 27th 2024

MRD, Clinical Outcomes Linked in Chronic Leukemia

Gayle Turim Dickstein
This systematic review focusing on the targeted therapy era found solid associations between measurable residual disease (MRD) and clinical outcomes in patients with chronic lymphocytic leukemia.
cancer treatment | Image Credit: tashatuvango-stock.adobe.com
July 20th 2024

Study Reveals Top Treatment Priorities in Patients With CLL

Kimberly Rath, PharmD
Researchers of a new study explore what areas of chronic lymphocytic leukemia (CLL) treatment and care are important to patients and identify key areas for improvement.
Brian Koffman, MDCM, DCFP, FCFP, DABFP, MSEd, CLL Society
July 16th 2024

Advancements in CLL: A Conversation With Dr Brian Koffman

Brooke McCormick Maggie L. Shaw
In this interview from our coverage of the European Hematology Association 2024 Congress, we spoke with Brian Koffman, MDCM, DCFP, FCFP, DABFP, MSEd, executive vice president and chief medical officer of the CLL Society and himself a survivor of chronic lymphocytic leukemia (CLL), to discuss treatment advancements and the importance of addressing both unmet needs and patient treatment preferences.
CLL cells | Image credit: Laszlo - stock.adobe.com
July 13th 2024

Study Finds Pirtobrutinib Associated With Improved Outcomes vs Venetoclax in Relapsed CLL

Karen Jacobson-Sive
Pirtobrutinib led to improved outcomes compared with venetoclax in patients with relapsed chronic lymphocytic leukemia (CLL) following covalent Bruton tyrosine kinase inhibitor therapy.
A panel of 4 experts on CLL
July 12th 2024

Factors Influencing Choice of Second-Generation BTKi Monotherapy

Ryan Haumschild, PharmD, MS, MBA Roy Beveridge, MD Brian T. Hill, MD, PhD Adam S. Kittai, MD
Specialists discuss factors influencing the choices of second-generation BTK monotherapy.
A panel of 4 experts on CLL
July 12th 2024

Evaluating Value of BTK Inhibitors in CLL Treatment

Ryan Haumschild, PharmD, MS, MBA Roy Beveridge, MD Brian T. Hill, MD, PhD Adam S. Kittai, MD
Experts evaluate the value of BTK inhibitors in CLL treatment.
zanubrutinib | Image Credit: molekuul.be-stock.adobe.com
July 10th 2024

Zanubrutinib Safer Than Ibrutinib in Patients With B-Cell Malignancies

Karen Jacobson-Sive
A post-hoc analysis showed that zanubrutinib resulted in fewer adverse events compared with ibrutinib.
genetic mutation testing | Image Credit: JohanSwanepoel-stock.adobe.com
July 6th 2024

Report Recommends Strategy to Identify CLL in Patient With Posterior Uveitis

Jared Kaltwasser
It is rare for patients with chronic lymphocytic leukemia (CLL) to present with ocular involvement, but a mutational test could help clinicians identify patients more quickly.
Asian patient | Image Credit: kapinon-stock.adobe.com
July 2nd 2024

VenR Achieves Strong Results in Japanese CLL/SLL Cohort

Jared Kaltwasser
Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are rare in Japan, but a new report affirms the effectiveness of venetoclax (Venclexta) and rituximab (Rituxan) (VenR) in this population.
leukemia word map | Image Credit: dizain-stock.adobe.com
Published: June 28th 2024 | Updated: June 28th 2024

Infection Risk With BTK Inhibitors Low, New CLL Study Finds

Jared Kaltwasser
Only about 1% of patients with chronic lymphocytic leukemia (CLL) developed an invasive fungal infection while on a Bruton’s tyrosine kinase (BTK) inhibitor, investigators found.
A panel of 4 experts on CLL
June 28th 2024

CLL Treatment Landscape: Overview of BTK Inhibitors

Ryan Haumschild, PharmD, MS, MBA Roy Beveridge, MD Brian T. Hill, MD, PhD Adam S. Kittai, MD
A panel of experts provide an overview of BTK inhibitors for the treatment of patients with chronic lymphocytic leukemia.
A panel of 4 experts on CLL
June 28th 2024

Recent Trends and Innovations in the Management of CLL

Ryan Haumschild, PharmD, MS, MBA Roy Beveridge, MD Brian T. Hill, MD, PhD Adam S. Kittai, MD
Experts on the treatment of chronic lymphocytic leukemia discuss recent trends and innovations in the therapeutic landscape.
the word fatigue | Image Credit: andrew-stock.adobe.com
June 22nd 2024

Tired of It: Cancer-Related Fatigue in Lymphoma, CLL

Gayle Turim Dickstein
In the realm of lymphoma and chronic lymphocytic leukemia (CLL), and of the treatments that address them, a global survey of nearly 7000 patients proves there’s a long way to go to eliminate cancer-related fatigue from their lives.
leukemia diagnosis | Image Credit: Vitalii Vodolazskyi-stock.adobe.com
June 19th 2024

Transforming CLL Management With Emerging Prognostic Markers

Kimberly Rath, PharmD
This study provides a comprehensive review of both established and emerging prognostic markers in chronic lymphocytic leukemia (CLL), and their role in predicting disease, treatment response, and overall survival.
concept of heart issues | Image Creditz; ArtemisDiana-stock.adobe.com
June 15th 2024

Study Finds Genetic Indicators linked to BTK Inhibitor–Related Cardiotoxicity

Kimberly Rath, PharmD
Researchers have found that specific genetic markers may increase the risk of cardiovascular adverse effects in patients using Bruton’s tyrosine kinase (BTK) inhibitors.
Patient and doctor | Image Credit: ©DragonImages - adobe.stock.com
June 12th 2024

Formulary Switch From Ibrutinib to Zanubrutinib Yields Positive Safety, Efficacy Data

Christina Mattina
A real-world report showed the safety and efficacy of zanubrutinib after a community oncology practice replaced ibrutinib with the newer Bruton tyrosine kinase inhibitor on its formulary.
Stethoscope on charts | Image Credit: © amazing studio - stock.adobe.com.jpeg
June 7th 2024

Next-Gen BTKis Show Efficacy, Safety Edge Over Ibrutinib in Real-World Setting

AJMC Contributor
An abstract presented at the 2024 American Society of Clinical Oncology annual meeting showed that patients treated with zanubrutinib or acalabrutinib had more favorable safety and efficacy outcomes.
Medical data | Image Credit: © everythingpossible - stock.adobe.com
June 6th 2024

Real-World Database Yields New Potential Safety Signals for Bendamustine

Jared Kaltwasser
The authors said their analysis should help clinicians better monitor patients for potential adverse events.
CLL on a keyboard | Image Credit: © momius - stock.adobe.com
June 4th 2024

Long-Term Analysis From DUO Trial Affirms Benefits of Duvelisib

Jared Kaltwasser
The new data shed light on long-term outcomes for patients receiving duvelisib, although the investigators said the treatment landscape has also shifted significantly since the original trial.
Blood smear from a cancer patient | Image Credit: Chansom Pantip-stock.adobe.com
May 31st 2024

BET Inhibition Reduces CLL Burden, Boosts Immune Function

Kimberly Rath, PharmD
BET inhibition in chronic lymphocytic leukemia (CLL) significantly reduces leukemic cell burden and restores T-cell function by modulating the immune microenvironment and reversing T-cell exhaustion.
Patient in a hospital bed with doctor | Image credit: Tyler Olson - stock.adobe.com
May 21st 2024

SID Heightens Infection Risk in Patients With B-Cell Malignancies

Jared Kaltwasser
A new report finds secondary immunodeficiency disease (SID) also increases the risk of mortality in patients with B-cell malignancies.
Liver scan by a robot | Image Credit: adisak-stock.adobe.com
May 21st 2024

Unique Case: HCC With No Cirrhosis—and “Hidden” CLL/SLL

Gayle Turim Dickstein
A 77-year-old man had no risk factors for hepatocellular carcinoma (HCC), but he was nonetheless found to have it. Along the way, he was also diagnosed with previously undetected chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
Ibrutinib Shows Similar Efficacy Across Trials in Chronic Lymphocytic Leukemia
May 17th 2024

Ibrutinib Shows Similar Efficacy Across Trials in Chronic Lymphocytic Leukemia

Luke Halpern
Matching-adjusted indirect comparison methodology was utilized to compare ibrutinib arms across the ALPINE and ELEVATE-RR trials.
Lymphoma word block image | Image Credit: airdone-stock.adobe.com
May 15th 2024

Important Insights Regarding Primary Breast Lymphoma

Luke Halpern
Due to the rarity of primary breast lymphoma, individualized treatment plans that consider overall health, symptoms, and patient preferences should be curated.
Nurse holding older woman's hands - Cecilie Arcurs/peopleimages.com - stock.adobe.com.jpeg
May 10th 2024

Persistence Pays Off With Zanubrutinib: A Challenging CLL Case With a Prior BTK Inhibitor Failure

Gayle Turim Dickstein
The case of a 77-year-old woman with a long chronic lymphocytic leukemia (CLL) history illustrates the novel use of zanubrutinib as a potential option for some patients who have failed first-generation Bruton tyrosine kinase (BTK) inhibitors and venetoclax.
Image of a doc reviewing a case report | Image Credit: fedrunovan - stock.adobe.com
May 8th 2024

CLL Followed by CML: A Rare Case Described

Gayle Turim Dickstein
A very unusual case of 2 chronic leukemias, chronic lymphocytic leukemia (CLL) and secondary chronic myeloid leukemia (CML) existing simultaneously in an older patient was treated with a pair of targeted kinase inhibitors.
Enhanced image of leukemia | Image Credit: freshidea - stock.adobe.com
May 2nd 2024

Targeted Therapies for CLL Can Lead to Improved Patient Outcomes

Luke Halpern
There was a marked increase in the prevalence of targeted therapy among patients with chronic lymphocytic leukemia (CLL), which corresponded to positive overall survival rates observed in the study.
<123456>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo